Charles River Laboratories Stock Surges 15% in Morning Trading Amid Strong Earnings and Revenue Growth
ByAinvest
Thursday, Jul 24, 2025 5:53 am ET1min read
CRL--
Analysts have forecasted an average target price of $158.53 for CRL, with a high estimate of $200 and a low estimate of $70. The average target implies a 4.49% downside from the current price of $165.99. The estimated GF Value for CRL in one year is $203.26, suggesting a 22.45% upside [1].
The company reported mixed results for the first quarter of 2025. Revenue decreased by 2.7% year-over-year, with an organic decline of 1.8% across all business segments. However, the company's operating margin increased by 60 basis points year-over-year, driven by cost savings from restructuring initiatives. Earnings per share (EPS) rose by 3.1% from the first quarter of 2024, supported by improvements in operating margin and reductions in tax rate and interest expense [1].
CRL's stock price surge can be attributed to investor interest and confidence in the company's potential growth and performance. The company is actively investing in New Approach Methods (NAMs) and has a growing portfolio of capabilities in preclinical drug development, positioning itself as a leader in the field [1].
References:
[1] https://www.gurufocus.com/news/2994183/charles-river-crl-stock-rises-over-15-in-morning-trading-crl-stock-news
[2] https://www.inkl.com/news/d-r-horton-iqvia-holdings-northrop-grumman-and-other-big-stocks-moving-higher-on-tuesday
[3] https://finance.yahoo.com/news/look-fair-value-charles-river-143909176.html
IQV--
Charles River Laboratories (CRL) stock price rose by $15.11 to $164.90 in morning trading, marking a notable gain in the liquid option market. Analysts forecast an average target price of $158.53, with a high estimate of $200 and a low estimate of $70. The average target implies a 4.49% downside from the current price. The estimated GF Value for CRL in one year is $203.26, suggesting a 22.45% upside.
Charles River Laboratories (CRL) stock price experienced a significant increase in morning trading, rising by $15.11 to reach $164.90. This upward movement positions CRL among the top performers in the liquid option market [1].Analysts have forecasted an average target price of $158.53 for CRL, with a high estimate of $200 and a low estimate of $70. The average target implies a 4.49% downside from the current price of $165.99. The estimated GF Value for CRL in one year is $203.26, suggesting a 22.45% upside [1].
The company reported mixed results for the first quarter of 2025. Revenue decreased by 2.7% year-over-year, with an organic decline of 1.8% across all business segments. However, the company's operating margin increased by 60 basis points year-over-year, driven by cost savings from restructuring initiatives. Earnings per share (EPS) rose by 3.1% from the first quarter of 2024, supported by improvements in operating margin and reductions in tax rate and interest expense [1].
CRL's stock price surge can be attributed to investor interest and confidence in the company's potential growth and performance. The company is actively investing in New Approach Methods (NAMs) and has a growing portfolio of capabilities in preclinical drug development, positioning itself as a leader in the field [1].
References:
[1] https://www.gurufocus.com/news/2994183/charles-river-crl-stock-rises-over-15-in-morning-trading-crl-stock-news
[2] https://www.inkl.com/news/d-r-horton-iqvia-holdings-northrop-grumman-and-other-big-stocks-moving-higher-on-tuesday
[3] https://finance.yahoo.com/news/look-fair-value-charles-river-143909176.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet